Previously recorded as Biomedicines, Inc. (to 2004)
27 patents currently held
5 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
8 more records may belong here and await a decision; they are not counted.
The next term ends in Aug 2027. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
11
Ending by 2030
Aug 2027
Next term end
15
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends May 2028 · High confidence
Also notable
Ends Sep 2029 · High confidence
Also notable
Ends Aug 2027 · High confidence
Also notable
Ends Aug 2027 · High confidence
Also notable
Ends Apr 2031 · High confidence
Also notable
Ends Jul 2028 · High confidence
Also notable
Ends May 2037 · High confidence
Also notable
Ends Sep 2035 · High confidence
Composition and Dosage Form Comprising an Interferon Particle Formulation and Suspending Vehicle
US 7,731,947
The most cited patent in this portfolio, cited by 145 later US patents, top 5% of utility patents granted in 2010 in our data. Protection runs to 2028.
Devices, Formulations, and Methods for Delivery of Multiple Beneficial Agents
US 8,926,595
Cited by 84 later US patents, top 5% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2029.
Solvent/Polymer Solutions as Suspension Vehicles
US 8,114,437
Cited by 99 later US patents, top 10% of utility patents granted in 2012 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027. A terminal disclaimer caps this term to an earlier patent's.
Osmotic Delivery Systems and Piston Assemblies for Use Therein
US 7,682,356
Cited by 133 later US patents, top 5% of utility patents granted in 2010 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027.
Rapid Establishment And/Or Termination of Substantial Steady-State Drug Delivery
US 8,298,561
Cited by 69 later US patents, top 10% of utility patents granted in 2012 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2031.
Polyoxaester Suspending Vehicles for Use with Implantable Delivery Systems
US 7,959,938
Cited by 98 later US patents, top 10% of utility patents granted in 2011 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2028.
Glucagon-Receptor Selective Polypeptides and Methods of Use Thereof
US 10,501,517
Cited by 21 later US patents, top 25% of utility patents granted in 2019 in our data. Protection runs to 2037.
THERAPEUTIC METHODS FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS FOR PATIENTS WITH HIGH BASELINE HbA1c
US 9,889,085
Cited by 18 later US patents, top 25% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2035.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 23, 2026The maintenance fee for Methods Comprising Continuous Administration of Exenatide and Co-Administration of a Drug (US 11,654,183) comes due Nov 23, 2026. Unpaid by May 24, 2027, it lapses early.
- 1 fee due Feb 28, 2027The maintenance fee for Long Acting Peptide Tyrosine Tyrosine (PYY) Analogs and Methods of Use (US 11,739,134) comes due Feb 28, 2027. Unpaid by Aug 30, 2027, it lapses early.
- 1 fee due Apr 15, 2027The maintenance fee for Devices, Formulations, and Methods for Delivery of Multiple Beneficial Agents (US 10,441,528) comes due Apr 15, 2027. Unpaid by Oct 15, 2027, it lapses early.
- 1 fee due Jun 10, 2027The maintenance fee for Glucagon-Receptor Selective Polypeptides and Methods of Use Thereof (US 10,501,517) comes due Jun 10, 2027. Unpaid by Dec 10, 2027, it lapses early.
- 1 fee due Jul 7, 2027The maintenance fee for Osmotic Delivery Systems and Piston Assemblies for Use Therein (US 10,527,170) comes due Jul 7, 2027. Unpaid by Jan 7, 2028, it lapses early.
- 1 fee due Sep 10, 2027The maintenance fee for THERAPEUTIC METHODS FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS FOR PATIENTS WITH HIGH BASELINE HbA1c (US 10,583,080) comes due Sep 10, 2027. Unpaid by Mar 10, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The largest of its 15 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,682,356 | Osmotic Delivery Systems and Piston Assemblies for Use Therein In force · High confidence | In force | High confidence | |
| US 7,879,028 | Osmotic Delivery Systems and Piston Assemblies for Use Therein In force · High confidence | In force | High confidence | |
| US 8,114,437 | Solvent/Polymer Solutions as Suspension Vehicles In force · High confidence | In force | High confidence | |
| US 7,731,947 | Composition and Dosage Form Comprising an Interferon Particle Formulation and Suspending Vehicle In force · High confidence | In force | High confidence | |
| US 7,959,938 | Polyoxaester Suspending Vehicles for Use with Implantable Delivery Systems In force · High confidence | In force | High confidence | |
| US 8,940,316 | An osmotic delivery device comprising an insulinotropic peptide and uses thereof In force · Medium confidence | In force | Medium confidence | |
| US 10,527,170 | Osmotic Delivery Systems and Piston Assemblies for Use Therein In force · High confidence | In force | High confidence | |
| US 8,052,996 | Two-Piece, Internal-Channel Osmotic Delivery System Flow Modulator In force · Medium confidence | In force | Medium confidence | |
| US 10,441,528 | Devices, Formulations, and Methods for Delivery of Multiple Beneficial Agents In force · Medium confidence | In force | Medium confidence | |
| US 8,926,595 | Devices, Formulations, and Methods for Delivery of Multiple Beneficial Agents In force · High confidence | In force | High confidence |
Also on record, not counted in the 27: 5 patents in force now held by others · 56 patents ended · 44 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.